期刊文献+

血清FGF-21水平与非酒精性脂肪性肝病的相关性 被引量:2

Study on serum level of FGF-21 correlating with non-alcoholic fatty liver disease and its non-invasive diagnostic value
下载PDF
导出
摘要 目的探讨成纤维细胞生长因子21(FGF-21)与非酒精性脂肪性肝病(NAFLD)进展的相关性,无创预测诊断非酒精性脂肪性肝炎(NASH)。方法选取NAFLD患者80例,正常健康人群50例作为对照。测量身高、体质量、腰围等生理指标,计算BMI;检测ALT、AST、AST/ALT、ALP、GGT、TC、TG、HDL、LDL等生化指标;双抗夹心法测定血清中FGF-21浓度水平。结果血清FGF-21与AST及低密度脂蛋白胆固醇具有相关性(P<0.05),与肝细胞脂肪变性、气球样变、小叶内炎症、汇管区炎症及纤维化程度呈高度相关(P<0.01);随NAS评分增高其浓度增大,呈高度正相关(r=0.881,P<0.01);NASH患者血清中FGF-21明显高于Non-NASH患者(t=0.127,P<0.01),经ROC曲线分析,AUC=0.977,利用Youden指数确定最佳敏感性为97.4%,特异性为91.7%,最佳cut-off值为40.76 ng/L,具有较高的诊断能力。结论 NASH患者血清FGF-21水平明显升高,血清FGF-21可作为评价NASH及其严重程度的独立预测因子,可以作为一个无创性诊断指标对NASH进行诊断。 Objective To investigate the correlation between fibroblast growth factor (FGF) 21 and progression of non‐alcoholic fatty liver disease (NAFLD) and its non‐invasive diagnostic value .Methods Eighty cases confirmed diagnosis of NAFLD by liver biopsy were enrolled .Liver biopsy tissues were collected ,and serum samples were collected 1 week before biopsy .Fifty cases diagnosed of no fatty liver by B‐ultrasound were enrolled as controls .Measurements of height , weight ,waist circumference and other physiological indicators were carried out ,and body mass index (BMI) were calculated .Levels of alanine aminotransferase (ALT ) , aspartate aminotransferase (AST ) , AST / ALT , alkaline phosphatase (ALP) ,gamma‐glutamyl transpeptidase (GGT) ,total cholesterol (TC) ,triglyceride (TG) ,high density lipoprotein (HDL) ,low density lipoprotein (LDL) and other biochemical markers were detected .Enzyme‐linked immuno‐sorbent assay (ELISA) was performed to determine the concentration of serum FGF‐21 .Results Serum level of FGF‐21 was associated with AST and LDL (P〈 0 .05) ,and highly correlated with hepatic steatosis ,ballooning degeneration , lobular inflammation ,periportal inflammation and fibrosis degree (P〈0 .01) .Serum level of FGF‐21 increased with NAS score increasing ,which indicated a high‐positive correlation (r=0 .881 ,P〈0 .01) .Furthermore ,serum level of FGF‐21 in non alcoholic steatohepatitis (NASH) patients was significantly higher than that in non‐NASH patients (t=0 .127 , P〈0 . 01) by receiver operating characteristic(ROC) curve analysis (AUC=0 .977) .Optimum sensitivity ,specificity and the best cut‐off value were determined by Youden index as 97 .4% ,91 .7% and 40 .76 ng/L ,respectively ,which revealed high diagnostic value of FGF‐21 .Conclusion Serum levels of FGF‐21 in patients with NASH were significantly increased ,which could be an independent predictor to evaluate NASH and its severity and a non‐invasive diagnostic indicator for NASH .
出处 《肝脏》 2015年第9期686-690,共5页 Chinese Hepatology
基金 首都卫生发展科研专项项目(首发2014-2-5032) 中国肝炎防治基金会王宝恩肝纤维化研究基金(CFHPC20131020) 解放军第三〇二医院院长创新基金(YNKT2013041)
关键词 成纤维细胞生长因子21 NASH 无创诊断 Fibroblast growth factor 21 NASH Non-invasive diagnostic
  • 相关文献

参考文献23

  • 1Clark JM,Brancati FL,Diehl AM.The prevalence and etiology of elevated aminotransferase levels in the United States.Am J Gastroenterol,2003,98:960-967.
  • 2Kim WR,Brown RS Jr,Terrault NA,et al.Burden of liver disease in the United States:summary of a workshop.Hepatology,2002,36:227-242.
  • 3Lonardo A,Adinolfi LE,Loria P,et al.Steatosis and hepatitis C virus:mechanisms and significance for hepatic and extrahepatic disease.Gastroenterology,2004,126:586-597.
  • 4Lonardo A,Sookoian S,Chonchol M,et al.Cardiovascular and systemic risk in nonalcoholic fatty liver disease-atherosclerosis as a major player in the natural course of NAFLD.Curr Pharm Des ?2013,19:5177-5192.
  • 5Musso G,Anty R,Petta S.Antioxidant therapy and drugs interfering with lipid metabolism:Could they be effective in NAFLD patients? Curr Pharm Des,2013,19:5297-5313.
  • 6Ahmed MH,Barakat S, Almobarak AO.Nonalcoholic fatty liver disease and cardiovascular disease:has the time come for cardiologists to be hepatologists? J Obes,2012,2012:483135.
  • 7Day CP,James OF.Steatohepatitis:a tale of two "hits"? Gastroenterology,1998,114:842-845.
  • 8Farrell GC,Larter CZ,Nonalcoholic fatty liver disease:from steatosis to cirrhosis.Hepatology,2006,43:S99-S112.
  • 9Kumar KS, Malet PF.Nonalcoholic steatohepatitis.Mayo Clin Proc,2000,75:733-739.
  • 10Matteoni CA,Younossi ZM,Gramlich T,et al.Nonalcoholic fatty liver disease:a spectrum of clinical and pathological severity.Gastroenterology,1999,116:1413-1419.

共引文献283

同被引文献14

引证文献2

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部